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Bovine respiratory disease is a serious health and economic problem for dairy and beef cattle indus-
tries worldwide.1,2 This disease complex is frequently 
characterized by a primary viral infection in combi-
nation with stress, which suppresses the host’s im-
mune system, damages the epithelium of the respira-
tory tract, and allows opportunistic bacteria such as 
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OBJECTIVE
To evaluate the effect of serum antibody abundance against bovine corona-
virus (BCV) on BCV shedding and risk of bovine respiratory disease (BRD) 
in beef calves from birth through the first 5 weeks in a feedlot.
ANIMALS
890 natural-service crossbred beef calves from 4 research herds.
PROCEDURES
Serial blood samples for measurement of serum anti-BCV antibody abun-
dance by an ELISA and nasal swab specimens for detection of BCV and 
other viral and bacterial BRD pathogens by real-time PCR methods were 
collected from all calves or subsets of calves at predetermined times from 
birth through the first 5 weeks after feedlot entry. Test results were com-
pared among herds, over time, and between calves that did and did not 
develop BRD. The associations of various herd and calf factors with test 
results were also evaluated.
RESULTS
At the calf level, serum anti-BCV antibody abundance was not associated 
with BCV shedding, but BCV shedding was positively associated with BRD 
incidence before and after weaning. The mean serum anti-BCV antibody 
abundance at weaning for a group of calves was inversely related with the 
subsequent incidence of BRD in that group; however, the serum anti-BCV 
antibody abundance at weaning for individual calves was not predictive of 
which calves would develop BRD after feedlot entry.
CONCLUSIONS AND CLINICAL RELEVANCE
Results indicated that serum anti-BCV antibody abundance as determined 
with ELISA were not associated with BCV shedding or risk of BRD in indi-
vidual beef calves from birth through the first 5 weeks after feedlot entry. 
(Am J Vet Res;78:1065–1076)
Mannheimia haemolytica, Pasteurella multocida, 
Histophilus somni, and Mycoplasma bovis to infect 
the lungs.3–5 The major viral pathogens associated 
with BRD include BVDV, BRSV, BHV1, and PI3.6,7 Al-
terations in innate defenses, leukocyte recruitment to 
the lungs, and production of proinflammatory cyto-
kines culminate in the pathological lesions associated 
with BRD.3 Although intervention strategies such as 
vaccination and metaphylactic or therapeutic admin-
istration of antimicrobials are commonly used to pre-
vent and treat respiratory tract disease in cattle, the 
incidence of BRD remains high.
Within the past decade, BCV has been identified 
as another important contributor to BRD.8 Bovine 
coronavirus is ubiquitous in cattle populations world-
wide and was initially associated with outbreaks 
of enteric disease. It is now recognized to have an 
etiologic role in 3 distinct clinical syndromes (diar-
rhea in calves, hemorrhagic diarrhea in adult cattle 
ABBREVIATIONS
BCV Bovine coronavirus
BHV1 Bovine herpesvirus-1
BRD Bovine respiratory disease
BRSV Bovine respiratory syncytial virus
BVDV Bovine viral diarrhea virus
BVDV1 Bovine viral diarrhea virus type 1
BVDV2 Bovine viral diarrhea virus type 2
Ct Cycle threshold
MLV Modified-live virus
PI3 Parainfluenza-3 virus
RT  Real-time
USMARC US Meat Animal Research Center
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[winter dysentery], and respiratory tract disease in 
cattle of all ages).8 Both killed virus and MLV vaccines 
are available to control enteric disease in calves and 
can be administered to calves at birth or to pregnant 
cows to induce production of anti-BCV antibodies 
in colostrum. Although all BCV isolates are believed 
to belong to a single serotype,8–12 results of a 2013 
study13 suggest that there may be differences in se-
roreactivity between strains isolated from the respi-
ratory tract and a commonly used enteric reference 
strain. However, there currently is no BCV vaccine 
licensed in the United States to aid in the prevention 
of BRD.8
Despite the fact that BCV has been associated 
with respiratory tract infections in cattle of all ages, 
its role in the pathogenesis of BRD in cattle at various 
production stages remains unclear. Most research on 
the association between BCV and BRD has involved 
feedlot cattle. Shedding of BCV in the absence of 
other important respiratory tract pathogens has been 
observed in cattle with naturally occurring BRD,14,15 
and BCV has been isolated from pneumonic lungs 
alone or in combination with other respiratory tract 
pathogens.7,14–18 Results of multiple studies14,19–23 indi-
cate that cattle with high anti-BCV antibody titers at 
feedlot entry are less likely to shed BCV and develop 
BRD than are cattle with low anti-BCV antibody ti-
ters at feedlot entry. However, it is not uncommon for 
apparently healthy feedlot cattle to shed BCV,14,21,23,24 
which raises questions about the respective associa-
tions of anti-BCV antibody titer and BCV shedding 
with the risk of BRD in feedlot cattle.
Compared with the information known about 
feedlot cattle, much less is known about the rela-
tionship between BCV and BRD in preweaned beef 
calves. Dairy calves, even those with fairly high pas-
sively (colostrum) or actively (vaccination) acquired 
anti-BCV antibody titers, can shed BCV during the 
first week after birth, and recurrent shedding of BCV 
by apparently healthy dairy calves is common, which 
suggests that many BCV infections are not associated 
with disease.25,26 To our knowledge, a comprehensive 
study to evaluate BCV shedding and anti-BCV anti-
body titers in preweaned beef calves (a population 
for which the risk of BRD differs substantially among 
both individual animals and herds over time) has not 
been conducted. Thus, the literature is lacking with 
regard to a temporal evaluation of BCV shedding, hu-
moral immunity to BCV, and the risk for development 
of BRD throughout the entire production cycle of 
beef cattle. The purpose of the study reported here 
was to evaluate the effect of serum anti-BCV antibody 
abundance on BCV shedding patterns and the inci-
dence of BRD in beef calves from birth through the 
first 5 weeks in a feedlot.
Materials and Methods
Animals
Eight hundred ninety natural-service cross-
bred beef calves born during April and May 2014 
were monitored from birth to the end of their fifth 
week in a feedlot. All study calves originated from 4 
herds that were managed in separate locations at the 
USMARC. Each of those 4 herds contained additional 
calves that were not enrolled in the study. Herds 1 
and 2 consisted of calves that were born as a result 
of artificial insemination or natural service, whereas 
herds 3 and 4 consisted of calves that were born as 
a result of natural service only. Only natural-service 
calves were enrolled in the study because calves that 
were born as a result of artificial insemination were 
enrolled in another study. All calves were managed 
in the same manner regardless of whether they were 
enrolled in the study reported here. The 4 herds did 
not have fence-line contact, so there was no direct 
pathogen transmission among herds. All experimen-
tal protocols were approved by the USMARC Insti-
tutional Animal Care and Use Committee (approval 
Nos. 5438-31000-082-04 and 3040-32000-031-07).
Vaccination schedule and calf processing
The cows (dams) in all 4 herds received an 
MLV vaccine-bacterin combination producta that 
contained antigens of BHV1, BVDV1, BVDV2, PI3, 
BRSV, and bacterins for Campylobacter fetus and 
5 serovars of Leptospira spp prior to breeding 
(approx June) annually. The dams were also vaccinat-
ed against enteric pathogens approximately 30 days 
before the beginning of calving season. That vaccineb 
contained killed strains of bovine rotavirus and BCV, 
a K99 Escherichia coli bacterin, and Clostridium 
perfringens type C toxoid to enhance the production 
and secretion of antibodies against those pathogens 
into the colostrum and aid in the prevention of diar-
rhea in calves.
Calves at approximately 20 to 70 days of age (June 
[same time as dams received prebreeding vaccine]) 
received an initial vaccination with an MLV vaccine-
bacterin combination productc that contained anti-
gens of BHV1, BVDV1, BVDV2, PI3, BRSV, and M hae-
molytica and a multivalent bacterin-toxoid productd 
intended to protect animals against disease caused by 
Clostridium chauvoei, Clostridium septicum, Clos-
tridium novyi, Clostridium sordellii, C perfringens 
types C and D, and Moraxella bovis. Calves at 111 to 
161 days of age (approx 21 days prior to weaning [ie, 
preconditioning]) received a booster of the respiratory 
vaccinec and another multivalent clostridial vaccinee 
intended to protect animals against disease caused by 
C chauvoei, C septicum, Clostridium haemolyti-
cum, C novyi, C sordellii, and C perfringens types 
C and D. Calves at approximately 130 to 190 days of 
age (weaning and feedlot entry) received another re-
spiratory vaccinef that contained antigens of BHV1, 
BVDV1, BVDV2, PI3, and BRSV.
Calves were weaned between September 24 
and October 3, 2014, and moved from their herds of 
origin to a feedlot where they were processed and 
commingled in 14 pens, each of which had capacity 
for approximately 70 calves. Calves were allocated 
to pens such that each pen contained the same pro-
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portion of calves from each of the 4 herds of origin. 
That method of allocation was chosen to maximize 
exposure among calves from all 4 herds and simulate 
the commingling of calves that occurs at commercial 
feedlots.
Over the next 5 weeks, calves with suspected 
BRD were removed from each pen for sample collec-
tion and treated in accordance with the standard op-
erating procedure established for cattle maintained 
at the USMARC. Diagnosis of BRD was made on the 
basis of the presence of clinical signs such as leth-
argy, anorexia, abnormal breathing, nasal and ocular 
discharge, and pyrexia. Calves were treated at the dis-
cretion of feedlot staff and the attending veterinarian, 
all of whom remained unaware of (were blinded to) 
the herd of origin for each calf at the time of BRD 
diagnosis. All adverse health events and treatments 
were recorded for each study calf so that associa-
tions between BRD and other comorbidities could be 
evaluated.
Sample collection procedures
A blood sample (approx 9 mL) for plasma acqui-
sition was collected between 18 and 48 hours after 
birth from a small subset (n = 34) of calves for which 
both birth and the first nursing episode were ob-
served. A blood sample (approx 9 mL at initial vac-
cination and 25 mL at preconditioning and weaning) 
for serum acquisition and nasal swab specimens were 
collected from all 890 calves at the time of each vac-
cination (initial vaccination, preconditioning, and 
weaning). Those 3 sample acquisition times were se-
lected to eliminate additional stress associated with 
excessive handling because calves were already be-
ing handled at those times for routine processing and 
vaccination.
Additional blood samples (approx 9 mL) and na-
sal swab specimens were obtained from each calf re-
moved from a pen because of suspected BRD (cases; 
n = 67) as well as apparently healthy calves (controls; 
109). Two controls were selected for sample collec-
tion from each pen on a weekly basis during the first 
4 weeks after feedlot entry. Because of a low number 
of cases in the fifth week, controls were selected only 
from the pens with cases. Controls were selected by 
use of a convenience method, rather than a random-
ized sampling method, to prevent or minimize stress 
associated with sorting needed to remove specific 
calves. Notches were made in the ear tags of calves 
treated for BRD as well as control calves to prevent 
those calves from being selected as controls at future 
sampling dates.
Blood samples were obtained by jugular ve-
nipuncture with an 18-gauge needle at 18 to 48 
hours after birth and initial vaccination and with a 
16-gauge needle at all sample acquisition times there-
after. Blood samples were centrifuged at 1,650 X g 
at 4°C for 25 minutes. Then, the plasma or serum 
from each sample was harvested and stored at –80°C 
until analysis.
Nasal swab specimens were obtained by passing 
2 sterile 6-inch-long cotton-tipped swabs into each 
nostril to swab the nasopharyngeal region. For each 
calf during each sample acquisition time, 1 nasal 
swab specimen from each nostril was obtained and 
placed into a cryovial that contained 1 mL of trans-
port medium (buffered peptone water with 12% glyc-
erol). Vials were snap-frozen in liquid nitrogen and 
stored at –80°C until analysis.
Detection of viral pathogens by use  
of RT-PCR assay
Real-time PCR methods were used to detect re-
spiratory viruses (BHV1, BVDV, BCV, and BRSV) in 
nasal swab medium that was used for transport and 
storage of nasal swab specimens. Viral shedding was 
determined for 60 calves that were randomly select-
ed by means of a random number generator from 
each of the 4 herds at each of the 3 routine sample 
acquisition times (initial vaccination, precondition-
ing, and weaning). That sample size was selected 
because it was calculated to have a 95% probability 
for detection of at least 1 infected animal if the true 
prevalence of viral shedding in the herd at the sample 
acquisition time was at least 5%.27 Viral shedding was 
also determined for cases and controls on the basis 
of disease status and sample collection date. Briefly, 
pools consisting of nasal swab medium from 5 calves 
were created on the basis of herd of origin at each 
routine sample acquisition time as well as on the ba-
sis of disease status (case or control) and sample col-
lection date.
Each pool contained 100 µL of nasal swab me-
dium from each of the 5 designated calves. From each 
pooled sample, RNA was extracted by use of a phe-
nol and guanidine isothiocyanate reagent,g and DNA 
was extracted with a silica membrane–based nucleic 
acid purification kit.h Then, an RT-PCR assay was per-
formed to detect the major viral pathogens associated 
with BRD (BHV1, BRSV, BVDV, and BCV). Primers 
and probes used for the assay were the same as those 
described in other studies.28–31 For each sample ana-
lyzed, cyclic amplification was conducted on a 25-µL 
reaction solution containing 2.5 µL each of extracted 
RNA and DNA, 4.5mM magnesium chloride, 400µM 
of deoxyribonucleotide triphosphate, 0.4µM concen-
tration of each primer, 0.2µM concentration of each 
probe, and 1 µL of an enzyme mixi with reverse tran-
scriptase and a hot-start Taq polymerase. Cycling 
conditions included reverse transcription at 50°C for 
30 minutes, inactivation of the reverse transcriptase 
enzyme and activation of the Taq polymerase at 95°C 
for 15 minutes, and 40 cycles of 94°C for 30 seconds, 
55°C for 60 seconds, and 72°C for 60 seconds. Posi-
tive, negative, no-template, and extraction control 
samples were included in each assay. Samples with 
a Ct value < 40 were considered to have positive 
results for the virus of interest. For pooled samples 
that yielded positive results for a particular virus, the 
RT-PCR assay was repeated on individual nasal swab 
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medium from each of the 5 calves that contributed to 
the pooled sample to identify the calf or calves that 
were shedding the virus of interest.
Detection of bacterial pathogens  
by RT-PCR assay
Samples of nasal swab medium collected from 
cases (calves with BRD) and controls during the first 
5 weeks after feedlot entry were sent to the Universi-
ty of Nebraska-Lincoln Veterinary Diagnostic Center 
for detection of M haemolytica, P multocida, H som-
ni, and M bovis by use of multiplex RT-PCR methods 
that have been validated for nasal swab specimens 
and lung tissue matrices obtained from cattle.j This 
RT-PCR assay was performed on individual samples 
(ie, samples were not pooled).
Detection of anti-BCV antibodies
For each of the 240 calves evaluated for BCV 
shedding at initial vaccination and weaning, serum 
anti-BCV antibody abundance was measured by use 
of a commercially available indirect antibody ELISAk 
in accordance with the manufacturer’s instructions. 
Serum anti-BCV antibody abundance was also mea-
sured in samples collected at initial vaccination and 
weaning for the 67 cases and 109 controls evaluated 
during the first 5 weeks after feedlot entry and in 
samples collected from birth through weaning for a 
small subset of calves from herds 3 (n = 21) and 2 (13) 
that did and did not, respectively, have evidence of 
BCV infection in preweaned calves. Briefly, test plates 
were assessed at a wavelength of 450 nm with a com-
puter-linked ELISA plate reader.l Optical density of 
the tested sample was divided by the optical density 
of the positive control sample provided in the kit to 
calculate the anti-BCV antibody percentage positiv-
ity for the tested sample. Samples with a percentage 
positivity < 10 were considered negative for anti-BCV 
antibodies (seronegative), whereas those with a per-
centage positivity ≥ 10 were considered positive for 
anti-BCV antibodies (seropositive). A percentage pos-
itivity > 100 could be obtained if the concentration of 
anti-BCV antibodies in the tested sample was greater 
than that in the positive control sample provided in 
the kit. A dilution series for the positive control sam-
ple was used to determine the assay limit of linearity 
because the linear range for measurement of anti-
BCV antibodies was not provided by the manufactur-
er. Results indicated that the percentage positivity of 
the positive control sample had a good linear range 
from 10 to 100. When measured values were com-
pared with expected values, the linearity equation 
was Y = 1.657X – 0.08916, with R2 = 0.999. All test 
samples with results greater than that linear range 
were diluted and retested. The adjusted percentage 
positivity was calculated as the dilution factor of the 
sample multiplied by the percentage positivity, and 
that value was accepted as the relative anti-BCV anti-
body abundance.
Statistical analysis
Individual calves were the experimental unit for 
all analyses. Two-way contingency tablesm were cre-
ated, and χ2 tests were used to assess the respective 
associations between the development of BRD during 
the first 5 weeks after feedlot entry (case or control 
status) and BCV shedding and the presence of spe-
cific bacterial pathogens in the nasopharynx. The 
respective associations between serum anti-BCV anti- 
body ELISA results and herd of origin or case status 
were evaluated by use of a 1-way ANOVA followed 
by t tests for pairwise comparisons only if the over-
all F test was significant. Separate linear regression 
models were developed for the dependent variables 
of weaning age and weaning weight. Both models 
included fixed effects for herd of origin, case status, 
and the interaction between herd of origin and case 
status. Logistic regression analysis was used to deter-
mine the effect of herd on case status. All ANOVA and 
regression analyses were performed with a commer-
cially available statistical software program.n Values of 
P < 0.05 were considered significant for all analyses.
Results
Calves
The number of calves enrolled in the study from 
each herd, median dam parity within each herd, and 
mean ± SD weaning age and weight for the study 
calves were summarized (Table 1). Although cows in 
all 4 herds were exposed to bulls during the same 60-
day period, the time during that period at which the 
study calves were conceived differed among herds. 
Thus, the mean weaning age and weaning weight of 
study calves differed among herds. Of the 890 calves 
enrolled in the study, 4 were excluded prior to wean-
ing because of injury or death, although none of the 
conditions were known to be related to infectious 
disease.
Respiratory virus shedding and BRD  
incidence prior to feedlot entry
Shedding of each of 4 respiratory viruses (BHV1, 
BVDV, BRSV, and BCV) in 60 randomly selected study 
calves from each herd was determined at initial vac-
cination (20 to 70 days old), preconditioning (111 to 
161 days old), and weaning (130 to 190 days old). Bo-
vine viral diarrhea virus was not detected in any calf 
at any sample acquisition time prior to feedlot entry. 
Bovine herpesvirus-1 was detected in 2 calves of herd 
4 at weaning; BRSV was also detected in 1 of those 
calves. The number of calves from which BCV was de-
tected in nasal swab specimens was summarized (Ta-
ble 2). Bovine coronavirus was detected in 14 (23%) 
calves of herd 3 at initial vaccination and 8 (13%) and 
9 (15%) calves of herds 1 and 3, respectively, at wean-
ing. The overall prevalence rate of BCV shedding was 
6% (14/240) at initial vaccination, 0% at precondition-
ing, and 7% (17/240) at weaning, and the overall preva-
lence rate of BCV shedding prior to feedlot entry was 
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4% (8/180) for herd 1, 0% for herd 2, 13% (23/180) for 
herd 3, and 0% for herd 4. The incidence of BRD (de-
fined as the presence of lethargy, anorexia, abnormal 
breathing, nasal and ocular discharge, and pyrexia) 
in calves prior to feedlot entry differed among the 4 
herds and ranged from 0% (herds 2 and 4) to 11% (herd 
3). The incidence rate of BRD in calves prior to feedlot 
entry for herd 3 (25/226 [11%]) was significantly great-
er than that for herd 1 (2/138 [1.5%]). None of the 27 
calves that developed BRD prior to feedlot entry had 
comorbidities such as diarrhea, and only 3 calves were 
treated for diarrhea prior to feedlot entry.
Respiratory virus shedding and BRD 
incidence during the first 5 weeks after 
feedlot entry
Of the calves enrolled in the study, 70 (7.9%) de-
veloped BRD during the first 5 weeks after feedlot 
entry (cases). The incidence rate of BRD in calves 
during the first 5 weeks after feedlot entry differed 
among the 4 herds of origin. The incidence rate of 
BRD for herd 2 (51/413 [12%]) was significantly great-
er than that for herds 1 (3/138 [2%]), 3 (12/226 [5%]), 
and 4 (4/113 [4%]).
Of the 70 cases, 39 (55.7%) were steers and 31 
(44.3%) were heifers. The cases were distributed fairly 
equally among the 14 pens, with at least 1 BRD case 
identified in 11 pens during the first week after feedlot 
entry (Supplementary Table S1, available at avma-
journals.avma.org/doi/suppl/10.2460/ajvr.78.9.1065). 
Although controls were selected on the basis of conve-
nience, neither the mean weaning age nor mean wean-
ing weight differed significantly between cases and con-
trols regardless of whether herd of origin was or was 
not controlled (data not shown), which suggested that 
the case and control populations were well matched.
Sixty-seven of the 70 BRD case samples were 
available for analysis. Bovine viral diarrhea virus was 
detected in 1 case, and sequence analysis of the 5′ un-
translated region of the isolated virus revealed that it 
was a BVDV1a strain that was 98% homologous to the 
NADL strain used in the administered MLV vaccine 
(data not shown). Bovine herpesvirus-1 and BRSV 
were not detected in any calf during the first 5 weeks 
after feedlot entry.
Bovine coronavirus RNA was detected in nasal 
swab specimens from 65 of 67 (97%) cases and 64 of 
109 (59%) controls (Table 3) and was detected in all 
cases and controls sampled during the first 2 weeks af-
ter feedlot entry. However, for calves that had positive 
results for BCV (Ct < 40) by use of the RT-PCR assay, the 
mean Ct value was significantly (P < 0.001) lower for 
cases than for controls during the first week after feed-
lot entry (Figure 1), which suggested that cases were 
Table 1—Descriptive characteristics for 890 natural-service crossbred beef calves born in 4 USMARC herds during April and May 
2014 that were monitored from birth to the end of their fifth week in a feedlot to evaluate the effect of serum anti-BCV antibody 
abundance on BCV shedding and the incidence of BRD.
 Herd
Variable 1 2 3 4 
Total No. of calves 534 624 241 116
No. of calves enrolled in study 138 413 226 113
Dam parity 2.5 (1–4) 5.2 (2–9) 7.3 (4–11) 6.0 (4–8)
Weaning age (d) 146 ± 12a,b 148 ± 18a 162 ± 17c 158 ± 15b,c
Weaning weight (kg) 203 ± 23a 211 ± 31a 236 ± 33b 236 ± 31b
No. (%) of study calves 2 (1.5) 0 (0) 25 (11) 0 (0)
  that developed BRD prior
  to feedlot entry
No. (%) of study calves 
   that developed BRD  3 (2) 51 (12) 12 (5) 4 (4)
   during the first 5 wk after
   feedlot entry
Values represent the mean ± SD or median (range) unless otherwise specified. A diagnosis of BRD was made on the basis of the presence of 
lethargy, anorexia, abnormal breathing, nasal and ocular discharge, and pyrexia.
a–cWithin a row, values with different superscript letters differ significantly (P < 0.05).
Table 2—Number (percentage) of calves from which BCV was detected in nasal swab specimens at initial vaccination (20 to 70 
days old), preconditioning (111 to 161 days old), and weaning (130 to 190 days old).
 Herd       
Sample acquisition time 1 2 3 4 Total 
Initial vaccination 0 (0) 0 (0) 14 (23) 0 (0) 14 (6)
Preconditioning 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Weaning 8 (13) 0 (0) 9 (15) 0 (0) 17 (7)
Total 8 (4) 0 (0) 23 (13) 0 (0) 31 (4)
For each herd at each specified sample acquisition time, nasal swab specimens from 60 arbitrarily selected calves were assayed by use of RT-
PCR assay for determination of BCV shedding.
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shedding a greater amount of BCV in their nasal secre-
tions than controls during that week. During weeks 
3, 4, and 5 after feedlot entry, BCV was not detected 
in any control that originated from herds 1 and 3 but 
was detected in 10 of 21 controls that originated from 
herd 2 and 2 of 10 controls that originated from herd 
4. Thus, the majority (10/12) of controls that had posi-
tive results for BCV during that period originated from 
herd 2. In contrast, BCV was detected in 24 of 26 (92%) 
cases during weeks 3, 4, and 5, and those BCV-positive 
cases originated from all herds, except herd 1. During 
the first 5 weeks after feedlot entry, cases were 23 times 
(OR, 23; 95% confidence interval, 5 to 142; P < 0.001) as 
likely to shed BCV as were controls. However, given that 
BCV was detected in all 41 cases and 52 controls evalu-
ated during the first 2 weeks after feedlot entry, weeks 
3 through 5 after feedlot entry were analyzed separate 
from weeks 1 and 2 after feedlot entry. During weeks 3 
through 5 after feedlot entry, cases were 45 times (OR, 
45; 95% confidence interval, 8 to 322; P < 0.001) as like-
ly to shed BCV as were controls.
Bacterial shedding and BRD incidence 
during first 5 weeks after feedlot entry
The numbers of cases and controls from which 
M haemolytica, P multocida, H somni, and M bovis 
were detected in nasal swab specimens during each 
of the first 5 weeks after feedlot entry were summa-
rized (Table 4). During week 4 after feedlot entry, 
the proportion of cases (11/12 [92%]) that had posi-
tive results for M bovis was significantly (P = 0.002) 
greater than the proportion of controls (8/26 [31%]) 
that had positive results for M bovis. However, the 
proportion of test-positive cases did not differ signifi-
cantly from the proportion of test-positive controls 
for any bacterial species evaluated during any other 
week. Additionally, for test-positive calves, the mean 
Ct value for cases did not differ significantly from the 
mean Ct value for controls for any bacterial species or 
week after feedlot entry (Figure 2), which indicated 
that, for each bacterial species evaluated, the relative 
abundance of bacteria (bacterial load) in the naso-
pharynx did not differ between cases and controls.
Effect of serum anti-BCV antibody 
abundance on BCV shedding
Relative serum anti-BCV antibody abundance 
for the calves from each herd that were evaluated 
Figure 1—Scatterplots of RT-PCR assay results for calves in 
which BCV was detected in nasal swab specimens and that did 
(cases; circles) or did not (controls; squares) develop BRD dur-
ing each of the first 5 weeks after feedlot entry. At feedlot entry, 
886 natural-service crossbred beef calves from 4 herds of origin 
were commingled and allocated among 14 pens such that each 
pen contained the same proportion of calves from each herd. 
Cases were defined as calves with clinical signs of BRD, includ-
ing lethargy, anorexia, abnormal breathing, nasal and ocular dis-
charge, and pyrexia. Controls were apparently healthy calves, 
and 2 controls were selected on the basis of convenience from 
each pen weekly for sample collection. Cases and controls were 
excluded from future sampling; thus, each case and control is 
represented only once in the figure. Results were reported as 
Ct values. The Ct value is inversely associated with the amount 
of BCV RNA detected; therefore, the lower the Ct value, the 
greater the amount of BCV RNA in the sample. Samples with a 
Ct value < 40 were considered to have positive results for BCV. 
For each scatterplot, the horizontal line represents the mean 
and the vertical line delimits the SD. *Within a given week, the 
mean Ct value differs significantly (P < 0.05) between cases and 
controls.
Table 3—Number of BRD case and control calves from which BCV was detected in nasal swab specimens during each of the first 
5 weeks after feedlot entry.
 Herd
  1 2 3 4 Total   
Time after  No.  No.  No.  No.  No. 
feedlot BRD positive No. positive No. positive No. positive No. positive No.
entry (wk) status for BCV sampled for BCV sampled for BCV sampled for BCV sampled for BCV sampled
1 Case 2 2 19 19 2 2 1 1 24 24
 Control 1 1 13 13 10 10 2 2 26 26
2 Case 0 0 13 13 2 2 2 2 17 17
 Control 4 4 8 8 8 8 6 6 26 26
3 Case 0 0 7 7 3 3 0 0 10 10
 Control 0 4 4 6 0 11 0 5 4 26
4 Case 0 1 8 8 2 3 0 0 10 12
 Control 0 5 6 12 0 5 2 4 8 26
5 Case 0 0 2 2 1 1 1 1 4 4
 Control 0 0 0 3 0 1 0 1 0 5
Total Case 2 3 49 49 10 11 4 4 65 67
 Control 5 14 31 42 18 35 10 18 64 109
Bovine coronavirus was detected by means of RT-PCR assay methods, and samples with a Ct value < 40 were considered to have positive results. 
See Table 1 for remainder of key.
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for BCV shedding at initial vaccination and weaning 
were plotted (Figure 3). At initial vaccination, BCV 
shedding was detected in 14 of 60 (23%) calves from 
herd 3 but was not detected in any calves evaluated 
from the other 3 herds. The calves evaluated from 
herd 3 had the highest mean relative anti-BCV anti-
Time after  BRD  No. positive No. positive  No. positive  No. positive 
feedlot entry (wk) status No. sampled for M haemolytica for P multocida for H somni for  M bovis
1 Case 24 8 8 13 0
 Control 26 7 9 9 0
2 Case 17 5 6 6 2
 Control 26 12 10 9 5
3 Case 10 6 6 5 5
 Control 26 12 17 8 4
4 Case 12 7 10 7 11*
 Control 26 10 20 7 8
5 Case 4 4 4 2 2
 Control 5 2 3 2 1
Total Case 67 30 (45) 34 (51) 32 (48) 20 (30)
 Control 109 43 (39) 59 (54) 35 (32) 18 (17)
All bacterial species were detected by means of RT-PCR assay methods, and samples with a Ct value < 40 were considered to have positive 
results for the bacterial species of interest. Numbers within parentheses represent the percentage of the total cases or controls.
*Within a week, the proportion of cases that had positive results for the given bacterial species differs significantly (P < 0.05) from the cor-
responding proportion for controls. 
See Table 1 for remainder of key.
Table 4—Number of case and control calves for which Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Myco-
plasma bovis were detected in nasal swab specimens during the first 5 weeks after feedlot entry.
Figure 2—Scatterplots of RT-PCR assay results for the cases (circles) and controls (squares) of Figure 1 in which Mannheimia 
haemolytica (A), Pasteurella multocida (B), Histophilus somni (C), and Mycoplasma bovis (D) were detected in nasal swab specimens 
during each of the first 5 weeks after feedlot entry. For all bacterial species, samples with a Ct value < 40 were considered to 
have positive results. See Figure 1 for remainder of key.
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body abundance (382), which was significantly great-
er than that for herds 1 (184) and 2 (254) but did not 
differ from that for herd 4 (317). The mean anti-BCV 
antibody abundance at initial vaccination for herd 1 
was significantly less than that for the other 3 herds, 
and that for herd 2 was significantly less than that for 
herd 3. Within herd 3, the mean anti-BCV antibody 
abundance did not differ significantly (P = 0.65) be-
tween calves that were and were not shedding BCV 
at initial vaccination.
At weaning, BCV shedding was detected in 8 of 
60 (13%) calves from herd 1 and 9 of 60 (15%) calves 
from herd 3. Mean relative anti-BCV antibody abun-
dance at weaning was greatest for the calves of herd 4 
(115) but did not differ significantly from that for the 
calves of herd 3 (106). Mean relative anti-BCV antibody 
abundance at weaning was lowest for the calves of 
herd 2 (45) and differed significantly from that for the 
calves of the other 3 herds. Herd 2 also had the high-
est proportion of calves that were seronegative for 
antibodies against BCV. Mean relative anti-BCV anti- 
body abundance at weaning for the calves of herd 1 
(89) was significantly greater than that for the calves 
of herd 4 but did not differ significantly from that for 
the calves of herd 3. At weaning, mean anti-BCV anti-
body abundance did not differ significantly between 
calves that were and were not shedding BCV within 
herds 1 (P = 0.22) and 3 (P = 0.37).
Effect of serum anti-BCV antibody 
abundance on BRD incidence during the 
first 5 weeks after feedlot entry
Within each herd, the mean relative anti-BCV 
antibody abundance at initial vaccination and wean-
ing did not differ significantly between cases and 
controls. Mean relative anti-BCV antibody abundance 
for all calves (cases and controls) did not differ sig-
nificantly among herds at initial vaccination but was 
significantly (P < 0.001) lower for the calves of herd 
2, compared with that for the calves from each of the 
other 3 herds, at weaning (Figure 4). Within herds, 
mean relative anti-BCV antibody abundance at wean-
ing was inversely associated with the proportion of 
cases. The incidence of BRD during the first 5 weeks 
after feedlot entry was greatest for calves that origi-
nated from herd 2 (51/413 [12%]), which also had the 
lowest mean relative anti-BCV antibody abundance. 
Herd 2 was also the only herd that had calves sero-
negative for anti-BCV antibodies at weaning (ie, feed-
Figure 3—Scatterplots of the relative serum anti-BCV 
antibody abundance for calves that were (squares) or were 
not (circles) shedding BCV at initial vaccination (20 to 70 
days old; A) and weaning (130 to 190 days old; B). Relative 
anti-BCV antibody abundance and BCV shedding were de-
termined for 60 randomly selected calves from each herd at 
both initial vaccination and weaning. a–cMean relative anti-
BCV antibody abundance for herds with different letters 
differs significantly (P < 0.05). See Figure 1 for remainder 
of key.
Figure 4—Scatterplots of the relative serum anti-BCV anti-
body abundance at initial vaccination (A) and weaning (B) for 
the cases (circles) and controls (squares) of Figure 1. *Mean 
relative anti-BCV antibody abundance for herd 2 differed sig-
nificantly (P < 0.001) from that for each of the other 3 herds. 
See Figure 1 for remainder of key.
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lot entry); 13 (8 cases and 5 controls) of 104 (12.5%) 
calves evaluated from herd 2 were seronegative for 
anti-BCV antibodies at weaning. When those 13 calves 
were removed from the analysis, mean anti-BCV anti-
body abundance for herd 2 was still significantly (P < 
0.001) lower than that for each of the other 3 herds 
(data not shown).
Relative anti-BCV antibody abundance 
over time in herds with and without  
evidence of BCV shedding prior  
to feedlot entry
Relative serum anti-BCV antibody abundance 
was plotted for a subset of calves from herds 2 (n 
= 13) and 3 (21) that were evaluated at all 3 sample 
acquisition times prior to feedlot entry (18 to 48 
hours old, initial vaccination, and weaning; Figure 
5). Prior to feedlot entry, BCV was not detected in 
nasal swab specimens from any of the calves evalu-
ated from herd 2 but was detected in nasal swab 
specimens from 23 of 180 calves evaluated from 
herd 3. The subset of calves evaluated from herd 
3 included 8 calves from which BCV was detect-
ed in nasal swab specimens prior to feedlot entry. 
Relative serum anti-BCV antibody abundance for 
samples collected from calves at 18 to 48 hours old 
likely reflected passively acquired (maternally de-
rived) anti-BCV antibodies, and the mean relative 
anti-BCV antibody abundance did not differ signifi-
cantly between herds 2 and 3 at that sample acqui-
sition time. However, the mean relative anti-BCV 
antibody abundance for herd 2 was significantly 
lower than that for herd 3 at both initial vaccina-
tion (P = 0.001) and weaning (P < 0.001).
Discussion
Although there is mounting evidence that BCV is 
involved in the etiology of BRD, information regard-
ing the respective temporal relationships between 
humoral immunity against BCV and BCV shedding 
and the risk for the development of BRD in beef 
calves at various times before and after feedlot en-
try is lacking. Results of the present study indicated 
that serum anti-BCV antibody abundance was not as-
sociated with BCV shedding; however, BCV shedding 
was positively associated with the incidence of BRD. 
Also, the mean serum anti-BCV antibody abundance 
for a group of calves was inversely related to the sub-
sequent incidence of BRD in that group. However, 
serum anti-BCV antibody abundance at weaning for 
individual calves within a group was not predictive of 
which calves would subsequently require treatment 
for BRD.
For the calves of the present study, the rate of 
BCV shedding prior to weaning differed among the 
4 herds of origin and over time; however, the BCV 
shedding pattern was not associated with serum anti-
BCV antibody abundance. Dams of the calves were 
vaccinated with a vaccine containing an enteric BCV 
strain 30 days before the start of calving season to 
facilitate the passive transfer of anti-BCV antibodies 
via colostrum and aid in the prevention of diarrhea 
in calves. We hypothesized that BCV-induced disease 
outbreaks would occur in preweaned calves when a 
certain proportion of that population lost protective 
immunity owing to the natural decline of maternally 
derived anti-BCV antibodies. However, despite signifi-
cant differences in the prevalence of BCV shedding 
among herds at the initial vaccination (20 to 70 days 
old) and weaning (130 to 190 days old) time points, 
no association was observed between mean anti-BCV 
antibody abundance and prevalence of respiratory vi-
rus shedding. Furthermore, within-herd analyses in-
dicated that the mean serum anti-BCV antibody abun-
dance did not differ significantly between calves that 
were and were not shedding BCV. These results sug-
gested that the serum anti-BCV antibody abundance 
as determined by use of a currently available ELISA 
did not accurately predict BCV shedding in individu-
al beef calves prior to weaning and were consistent 
with findings of studies25,26 involving preweaned 
dairy calves in which subclinical and recurrent BCV 
infections, albeit common, are not correlated with se-
rum anti-BCV antibody titers. Differences in the rate 
of BCV shedding by preweaned calves among the 4 
herds of origin were likely a function of the extent of 
exposure those calves had to the virus.
Contrary to serum anti-BCV antibody abundance, 
the prevalence of BCV shedding by preweaned calves 
in a herd appeared to be positively correlated with 
the incidence of BRD in those calves. The BRD inci-
dence rate in preweaned calves was greatest for herds 
Figure 5—Scatterplots of the relative serum anti-BCV anti- 
body abundance for a subset of calves from herds 2 (circles; 
n = 13) and 3 (squares; 21) that were evaluated at 18 to 48 
hours old, initial vaccination, and weaning. Prior to feedlot 
entry, BCV shedding was not detected in any of the calves 
evaluated from herd 2, but it was detected in 23 of 180 calves 
evaluated in herd 3. The subset of calves from herd 3 repre-
sented in this figure included 8 calves from which BCV was 
detected in nasal swab specimens prior to feedlot entry. 
*Within a sample acquisition time, mean relative anti-BCV 
antibody abundance differs significantly (P ≤ 0.001) between 
the 2 herds. See Figure 1 for remainder of key.
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1 (2/138 [1.4%]) and 3 (25/226 [11%]), the 2 herds in 
which calves shedding BCV were detected. Nasal swab 
specimens for pathogen detection were not collected 
at the time of BRD diagnosis from preweaned calves; 
therefore, it is unknown whether BCV was involved in 
the pathogenesis of clinical BRD in those calves. Herd-
level risk factors associated with BRD in preweaned 
beef calves include large herd size, incidence rate of 
diarrhea in calves, duration of calving season, and in-
troduction of cattle from outside sources.32–34 None of 
those factors were associated with the incidence of BRD 
in preweaned calves for the USMARC herds involved in 
the present study, although the introduction of outside 
cattle could not be assessed because those herds are 
closed populations. In another study,35 the incidence 
of BRD in preweaned calves was negatively associated 
with dam parity (ie, calves from young cows were more 
likely to develop BRD than calves from older cows), 
which the investigators attributed to improvements in 
the quality and quantity of colostrum and milk, and 
thereby the passive transfer of maternally derived anti- 
bodies to calves, as cows age. Interestingly, the herd 
with the highest incidence of BRD in preweaned calves 
in the present study (herd 3) had the highest median 
dam parity. Additionally, mean serum anti-BCV antibody 
abundance for calves at 18 to 48 hours old did not differ 
significantly between the herds that did (herds 1 and 3) 
and did not have (herds 2 and 4) BCV or BRD detected 
in preweaned calves, which further suggested that pas-
sive transfer of maternally derived anti-BCV antibodies 
was not associated with BCV shedding or the risk for 
development of BRD. In fact, in the study reported here, 
BCV shedding was the only factor evaluated that was 
significantly associated with BRD incidence in calves 
both before and after weaning.
In the present study, the prevalence of calves 
shedding BCV was fairly low prior to weaning, but it 
was quite high during the first 5 weeks after feedlot 
entry. In fact, BCV was detected in the nasal swab 
specimens collected from all calves that developed 
BRD (cases) and apparently healthy calves (controls) 
evaluated during the first 2 weeks after feedlot en-
try. This indicated that BCV infection was associated 
with both subclinical and clinical disease. However, 
the amount of BCV RNA detected in the nasal swab 
specimens of cases was significantly greater than that 
detected in the nasal swab specimens of controls, 
which suggested that disease severity was positive-
ly associated with viral load. Results of other stud-
ies14,19,21,36–38 indicate that the rate of seroconversion 
to BCV can be as high as 100% in beef calves during 
the first few weeks after feedlot entry, which sug-
gests that BCV transmission among calves is common 
at feedlot entry. In the present study, BCV shedding 
remained a significant factor in the development of 
BRD in calves during weeks 3 through 5 after feed-
lot entry. Furthermore, during weeks 3 through 5 
after feedlot entry, M bovis was detected in nasal 
swab specimens from a significantly greater pro-
portion of cases (18/27 [67%]) than controls (13/57 
[23%]), which suggested that the presence of both 
BCV and M bovis in the nasopharynx in conjunction 
with other stressors (eg, weaning and changing pens) 
may have contributed to the development of BRD in 
calves during that period.
The role of BCV in the development of BRD 
in calves was further supported by the fact that, 
in the present study, the mean serum anti-BCV an-
tibody abundance for a group of calves at weaning 
was inversely associated with the incidence of BRD 
for those calves during the first 5 weeks after feed-
lot entry. Mean serum anti-BCV antibody abundance 
at weaning for the calves of herd 2 was significantly 
lower than that for the calves of the other 3 herds 
(Figure 4), and calves of herd 2 had the highest inci-
dence of BRD during the first 5 weeks after feedlot 
entry. As previously mentioned, mean serum anti-
BCV antibody abundance for calves at 18 to 48 hours 
old did not differ among the 4 herds; therefore, the 
differences observed at weaning were most likely 
the result of differences in BCV exposure rather than 
differences in passive transfer of maternally derived 
antibodies. The findings of the present study were 
consistent with results of other studies14,19–23 that 
have indicated BCV infection before weaning is pro-
tective against development of BRD after weaning 
and that calves with high serum anti-BCV antibody 
abundance at feedlot entry are less likely to develop 
BRD than calves with low serum anti-BCV antibody 
abundance. However, in the study reported here, 
contrary to other studies,14,21 the serum anti-BCV an-
tibody titer at weaning for individual calves was not 
predictive of which calves would be treated for BRD 
after feedlot entry.
The reasons serum anti-BCV antibody abun-
dance was not associated with BCV shedding or BRD 
incidence in preweaned and weaned beef calves in 
the present study are unknown. The ELISA used to 
measure anti-BCV antibodies in the present study 
detected total reactive rather than neutralizing 
antibodies. It is also possible that anti-BCV antibod-
ies generated in response to a natural infection might 
have had a weak protective effect against viral rep-
lication, which would protect against the develop-
ment of clinical signs of disease but not against virus 
shedding. That would be consistent with results of 
other studies, which indicate that subclinical BCV 
infections14,21,23–26 and recurrent or intermittent25,26 
shedding of BCV are common. It also may suggest 
a lack of long-term protective immunity after natu-
ral infection.8 The role of cell-mediated immunity in 
the mediation of viral shedding in calves with BRD is 
poorly characterized. It is possible that cell-mediated 
immune responses may correlate with BCV shedding 
and the development of BRD better than serum anti-
BCV antibody abundance. Finally, BCV shedding and 
the serum anti-BCV antibody abundance were evalu-
ated in the calves of this study fairly infrequently from 
birth through the first 5 weeks after feedlot entry. 
Thus, we based our results on a series of snapshots 
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in time. Calves that were not identified as BCV shed-
ders may have shed BCV between sample acquisition 
times, which might have masked the effect of serum 
anti-BCV antibody abundance on BCV shedding. Fu-
ture studies should be designed to distinguish be-
tween these possibilities and determine the best im-
mune correlates of protection for BCV infection.
In the present study, detection of BCV in nasal swab 
specimens obtained from preweaned beef calves was 
associated with the incidence of BRD in those calves 
before and after weaning. Also, the mean anti-BCV 
antibody abundance at weaning for a group of calves 
was inversely associated with the incidence of BRD 
for those calves after feedlot entry, which suggested 
that calves infected with BCV prior to weaning were 
protected against BRD after weaning and feedlot 
entry. However, the serum anti-BCV antibody abun-
dance at weaning for individual calves was not pre-
dictive of which calves would be treated for BRD 
after feedlot entry. Although BCV shedding (which 
was presumably indicative of infection) was not as-
sociated with death in the present study, BCV in-
fection can have adverse effects on calf health and 
well-being as well as feedlot productivity owing to a 
decrease in weight gain8,20 and increase in veterinary 
care costs for affected calves. Thus, generation of im-
munity against BCV in calves prior to feedlot entry 
should decrease the incidence of BRD and associated 
adverse animal health issues and production losses.20 
Further studies are necessary to elucidate the role of 
BCV in the pathogenesis of BRD in beef cattle at vari-
ous stages of the production cycle. Such information 
is necessary to guide BCV vaccine development and 
control strategies.
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d. Vision 7 with Spur, Merck, Kenilworth, NJ.
e. Vision 8, Merck, Kenilworth, NJ.
f. Bovi-Shield Gold 5, Zoetis, Florham Park, NJ.
g. TRIzol LS, Life Technologies, Grand Island, NY.
h. QIAamp DNA mini kit, Qiagen Inc, Valencia, Calif.
i. OneStep RT-PCR kit, Qiagen Inc, Valencia, Calif.
j. Pike L, Loy JD. Comparative assessment of multiplex PCR 
assays to culture and susceptibility testing methods for the 
detection of bovine bacterial respiratory pathogens and mac-
rolide antimicrobial resistance determinants (abstr), in Pro-
ceedings. 58th Annu Meet Am Assoc Vet Lab Diagn 2015;41.
k. BCV antibody ELISA, Boehringer Ingelheim Svanova, Uppsa-
la, Sweden.
l. Spectramax, Molecular Devices, Sunnyvale, Calif.
m. JavaStat. Medical Research Consulting, Madison, Wis. Available 
at: medrescon.tripod.com/ctab2x2.html. Accessed Mar 6, 2017.
n. SAS, version 16, SAS Institute Inc, Cary, NC.
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